China Biopharmaceuticals (01177) and Boehringer Ingelheim reached a strategic cooperation with a potential total value of 7 billion US dollars

Zhitongcaijing · 1d ago

Zhitong Finance App News, China Biopharmaceutical (01177) announced that the Group has signed a strategic option and licensing agreement (agreement) with Boehringer Ingelheim. This is the second cooperation between the two sides in the field of oncology. The two sides are committed to jointly establishing a long-term strategic partnership.

The agreement covers a total of six pre-clinical asset projects (projects) involving antibody-conjugated drugs (ADCs) and T-cell connectors (TCEs). Five of these projects are from Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (Lixin Pharmaceutical), a wholly-owned subsidiary of the Group, and one project comes from Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide), a subsidiary of the Group.

According to the agreement, the Group will lead the early development of these projects until the completion of global phase I clinical trials. After reaching the agreed clinical milestones, Boehringer Ingelheim is entitled to exercise the right of choice to obtain exclusive rights to (i) develop, manufacture and commercialize (i) four of these projects globally (excluding mainland China, Hong Kong and Macau) and (ii) the remaining two projects on a global scale.

The Group will receive a down payment of US$358 million and recent payments, and is entitled to receive potential exercise of options, development, regulation and commercialization milestone payments, totaling US$7 billion, and a maximum double digit royalty based on future product sales.

This strategic cooperation with Boehringer Ingelheim is an important milestone in the Group's international innovation strategy, further confirming the Group's R&D strength in the field of next-generation oncology therapy. By combining the Group's innovative platform and early development capabilities with Boehringer Ingelheim's global expertise in the field of oncology, the two sides aim to fully unlock the potential of such projects and bring innovative treatment options to patients around the world.